Senolytic drugs: from discovery to translation Kirkland JL, Tchkonia T Journal of Internal Medicine (2020) This comprehensive review from the Mayo Clinic's leading senescence researchers places FOXO4-DRI within the broader context of senolytic drug development and clinical translation
Raw-material quality does not replace finished-product potency, uniformity, disintegration and stability testing
Exosomes as new generation vehicles for drug delivery: biomedical applications and future perspectives
The protocol was approved by the IRBs named below
BPC-157 is not specifically named on the WADA Prohibited List as a separately listed substance, but as a non-approved substance with no marketing authorization it may fall under WADA section S0 (Non-Approved Substances), which prohibits substances not addressed by other sections of the List that have no current approval for human therapeutic use
Additionally, there is a controlling role of the pentadecapeptide BPC 157 against the tumor-promoting effects of many growth factors and peptides (Sikiric et al., 2018) as well as counteracting harmful escape from the initial healing effect (i.e., angiogenesis)
.jpg)
